Reference

1. Www.wikipdia.com
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin. 2018;68(6):394-424. doi:10.3322/ caac.21492
3. National Institutes of Health; National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/ breast.html. Accessed January 23, 2018.
4. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. Breast J. 2018;24(5):730-737. doi:10.1111/tbj.13034
5. Morrow M. Physical examination of the breast. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia, PA: Wolters
6. Kluwer Health; 2014:chap3. [3:02 pm, 09/11/2023] m: Weigelt, B.; Horlings, H.M.; Kreike, B.; Hayes, M.M.; Hauptmann, M.; Wessels, L.F.A.; De Jong, D.; van de Vijver, M.; Veer, L.J.V.;
7. Peterse, J.L. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008, 216, 141–150.
8. Erber, R.; Hartmann, A. Histology of Luminal Breast Cancer. Breast Care 2020, 15, 327–336
9. Howlader, N.; Altekruse, S.F.; Li, C.I.; Chen, V.W.; Clarke, C.A.; Ries, L.A.G.; Cronin, K.A. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. J. Natl. Cancer Inst. 2014, 106, djuOncolVIi
10. Weigelt, B.; Geyer, F.C.; Reis-Filho, J.S. Histological types of breast cancer: How special are they? Mol. Oncol. 2010, 4, 192–208.
11. Makki, J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin. Med. Insights Pathol. 2015, 8, 23–31.[CrossRef]
12. Raj-Kumar, P.-K.; Liu, J.; Hooke, J.A.; Kovatich, A.J.; Kvecher, L.; Shriver, C.D.; Hu, H. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. Sci. Rep. 2019, 9, 7956.
13. Ranjit, K. Breast cancer. Lancet 2005, 365, 1742.
14. Roberts, S.A.; Lawrence, M.S.; Klimczak, L.J.; Grimm, S.A.; Fargo, D.; Stojanov, P.; Kiezun, A.; Kryukov, G.; Carter, S.L.; Saksena, G.; et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013, 45, 970–976.
15. .Plasilova, M.L.; Hayse, B.; Killelea, B.K.; Horowitz, N.R.; Chagpar, A.B.; Lannin, D.R. Features of triple-negative breast cancer.
16. Newman, L.A.; Reis-Filho, J.S.; Morrow, M.; Carey, L.A.; King, T.A. The 2014 Society of Surgical Oncology Susan G. Komen for
17. the Cure Symposium: Triple-Negative Breast Cancer. Ann. Surg. Oncol. 2014, 22, 874–882. 2016, 95,subtyping.Pareja, F. Triple-negative breast cancer: The importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2016, 2, 16036.
18. Wetterskog, D. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast
19. Badve, S.; Dabbs, D.J.; Schnitt, S.J.; Baehner, F.L.; Decker, T.; Eusebi, V.; Fox, S.; Ichihara, S.; Jacquemier, J.;
20. Lakhani, S.R.; et al. Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2010, 24, 157–167.. J. Pathol. 2012, 226, 84–96
21. Prat, A.; Parker, J.S.; Karginova, O.; Fan, C.; Livasy, C.; Herschkowitz, J.I.; He, X.; Perou, C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12, R68.
22. Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.;
23. Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-MesenchymRes2
24. Transition and Stem Cell Characteristics. Cancer Res. 2009, 69, 4116–41Whel.Dias, K.; Dvorkin-Gheva, A.; Hallett, R.M.; Wu, Y.; Hassell, J.; Pond, G.R.; Levine, M.; Whelan, T.; Bane, A.L. Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. PLoS ONE 2017, 12, e0168669.
25. Morel, A.-P.; Ginestier, C.; Pommier, R.M.; Cabaud, O.; Ruiz, E.; Wicinski, J.; Devouassoux-Shisheboran, M.; Combaret, V.; Finetti, P.; Chassot, C.; et al. A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nat. Med. 2017, 23, 568–578
26. Acton, A. (2013). Breast Cancer New Insights for the Healthcare Professional. Atlanta, Georgia: Scholarly Editions.
27. .González-Jiménez, E., García, P., Aguilar, M., Padilla, C., & Álvarez, J. (2013). Breastfeeding and the Prevention of Breast Cancer: a Retrospective Review of Clinical Histories. Journal of Clinical Nursing, 23(1), 2397-2403.
28. 3.Kotsopoulos, J., Lubinski, J., Salmena, L., Lynch, H., Kim-Sing, C., Foulkes, W., Ghadirian, P., Neuhausen, S., Demsky, R., Tung, N., Ainsworth, P., Senter, L., Eisen, A., Eng, C., Singer, C., Ginsburg, O., Blum, J., Huzarski, T., Poll, A., Sun, P. and Narod, S. (2012). Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 14(2), p.R42
29. .Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.; Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Res. 2009, 69, 4116–4124.
30. Youtube.com ganeshay medical educganesha72
31. Hennessy, B.T.; Gonzalez-Angulo, A.-M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.-S.; Fridlyand, J.; Sahin, A.A.; Agarwal, R.; Joy, C.; et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Res. 2009, 69, 4116–4124.
32. Folkerd, E.; Dowsett, M. Sex hormones and breast cancer risk and prognosis. Breast 2013, 22, S38–S43.
33. Stat Bite: Lifetime Probability among Females of Dying of Cancer. JNCI J. Natl. Cancer Inst. 2004, 96, 1311–1321.9
34. Seal, S.; The Breast Cancer Susceptibility Collaboration (UK); Thompson, D.; Renwick, A.; Elliott, A.; Kelly, P.; Barfoot, R.; Chagtai, T.; Jayatilake, H.; Ahmed, M.; et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 2006, 38, 1239–1242
35. www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early- detection/mammograms.html
36. www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-ultrasound.html
37. www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html
38. www.cancer.org/cancer/diagnosis-staging/tests/imaging-tests/mri-for-cancer.html
39. Lumachi, F.; Luisetto, G.; Basso, S.M.M.; Basso, U.; Brunello, A.; Camozzi, V. Endocrine Therapy of Breast Cancer. Curr. Med. Chem. 2011, 18, 513–522. [CrossReBass3
40. Jones, K.L.; Buzdar, A.U. A review of adjuvant hormonal therapy in breast cancer. Endocr.-Related Cancer 2004, 11, 391–406 [CrossRef]
41. Rouzier, R.; Perou, C.; Symmans, W.F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K.R.; Stec, J.; Ayers, M.; Wagner, P.; et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clin. Cancer Res. 2005, 11, 5678–5685.[CrossRef]
42. Lumachi, F.; Luisetto, G.; Basso, S.M.M.; Basso, U.; Brunello, A.; Camozzi, V. Endocrine Therapy of Breast Cancer. Curr. Med. Chem. 2011, 18, 513–522. [CrossRef]
43. National Institutes of Health; National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/ breast.html. Accessed January 23, 2018.4XL
44. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. Breast J. 2018;24(5):730-737. doi:10.1111/tbj.13034
45. Caughran J, Braun TM, Breslin TM, et al. The effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: a longitudinal study. Breast J. 2018;24(5):730-737. doi:10.1111/tbj.13034